The site will also serve as the company's new headquarters, expanding its services in iPSC-based drug discovery, regenerative medicine, and cell therapy work.
The company is expanding its preclinical work on acute respiratory syndrome to investigate whether its fibroblasts may help with deadly lung inflammation, vascular leakage, and tissue damage.
The partnership hopes to speed up the scalable development of SC451 for type 1 diabetes by standardizing treatment protocols, improving clinical delivery and post-care, and preparing the therapy for broader use across...
The 4 US and 1 European patents cover the design and manufacturing of the company's placental therapies. The company is targeting various applications across orthopedics, urology, and wound care.
The therapy has been approved in the USA since 2024, and it'll soon be available down under as well, potentially reimbursed by Australia's pharma subsidy program.
The Korean biotech company published the multicenter Phase 1 results in Nature, with 24-week follow-up MRI data that look promising as they continue development.
Following their successful Phase 1, they've received clearance to begin Phase 2, where they'll assess whether it can reduce transfusion needs by calming the immune attack on bone marrow.
Cartherics is developing multiple immune cell therapies for women's health, including its lead candidate, CTH-401, a CAR-NK therapy targeting ovarian cancer.
The companies are working to bring jellyfish-derived Collagen Type Zero to North America, aiming to advance wound care and regenerative medicine with a sustainable alternative to mammalian collagen.
As MEDIPOST ventures abroad, Charles River will provide GMP-compliant biologics and cell therapy testing services to help advance the pipeline into new markets.
